Acadia Pharmaceuticals
ACAD
225 hedge funds and large institutions have $3.5B invested in Acadia Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 85 increasing their positions, 69 reducing their positions, and 45 closing their positions.
100.05% more ownership
Funds ownership: 0% → 100.05% (+100%)
23% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 69
6% more call options, than puts
Call options by funds: $103M | Put options by funds: $96.5M
4% less funds holding
Funds holding: 234 → 225 (-9)
7% less capital invested
Capital invested by funds: $3.75B → $3.5B (-$253M)
13% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 45
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$46.7M |
| 2 |
Jennison Associates
New York
|
+$36.3M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$30.3M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$29.6M |
| 5 |
SIG
Senator Investment Group
New York
|
+$22.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$31.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.1M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$23.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.4M |
| 5 |
VanEck Associates
New York
|
-$15.6M |
ACAD Hedge Fund Activity: Q4 2016 in Review
225 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2016, worth a combined $3.5B — down 6.7% from $3.75B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of ACAD and 39 opened new positions — a net loss of 6 holders — while 69 trimmed existing stakes and 85 added.
The largest buyer was Millennium Management, adding an estimated $46.7M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $31.2M sold.
- 225 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2016, down from 234 in Q3 2016.
- Funds reported $3.5B of Acadia Pharmaceuticals stock for Q4 2016, down 6.7% quarter-over-quarter.
- 39 funds opened new Acadia Pharmaceuticals positions in Q4 2016 and 45 closed out, a net change of -6 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2016 was Millennium Management, an estimated $46.7M added.
- The largest Acadia Pharmaceuticals seller in Q4 2016 was Eagle Asset Management, an estimated $31.2M sold.
Based on aggregated 13F filings for Q4 2016.